Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9-Reference-Cited by-同舟云学术

Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9

Published:2016-04-19 Issue:6 Volume:11 Page:1710-1719
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Ayaz Pelin¹,Andres Dorothee¹,Kwiatkowski Dennis A.¹,Kolbe Carl-Christian¹,Lienau Philip²,Siemeister Gerhard³,Lücking Ulrich⁴,Stegmann Christian M.¹

Affiliation:

1. Bayer Pharma AG, Drug Discovery, Lead Discovery Berlin, Berlin, Germany

2. Bayer Pharma AG, Drug Discovery, Research Pharmacokinetics, Berlin, Germany

3. Bayer Pharma AG, Drug Discovery, TRG Oncology, Berlin, Germany

4. Bayer Pharma AG, Drug Discovery, Medicinal Chemistry, Berlin, Germany

Funder

Seventh Framework Programme

European Federation of Pharmaceutical Industries and Associations

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.6b00074

Reference55 articles.

1. The Hallmarks of Cancer

2. Cell cycle kinases as therapeutic targets for cancer

3. Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation

4. Three RNA Polymerase II Carboxyl-terminal Domain Kinases Display Distinct Substrate Preferences

5. The history and future of targeting cyclin-dependent kinases in cancer therapy

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

2. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02

3. Solute solvent interaction study on 9,9-dihydroxynanoic acid by DFT, IR, Raman, UV, MEP, quantum parameters and docking studies;Journal of Molecular Liquids;2024-03

4. The anti-breast cancer activity of indeno[1,2-b]pyridin-5-one and their hydrazonal precursors endowed with anti-CDK-2 enzyme activity;Journal of Molecular Structure;2024-01

5. Progress in the Enantioselective Synthesis of Sulfur (VI) Compounds;Chemistry – A European Journal;2023-07-26